Rob Wills
Vice President, Alliance Management
Dr Wills is Vice President, Alliance Management, Johnson & Johnson. He is responsible for managing strategic alliances for the Pharmaceutical Group worldwide. This includes the relationships for Velcade, ceftobiprole, rivaroxaban, telaprevir, tapentadol, Yondelis and others. As head of Alliance Management, he oversees a small group of professionals who play an active role in the negotiations of alliances (structure, governance, dispute resolution, communication), in leading the integration post-signing and in managing the overall alliances. Prior to moving into this role in late 2001, Dr Wills spent 22 years in pharmaceutical drug development including, 12 of which have been at Johnson & Johnson.
In his previous role as Sr Vice President Global Development, he was responsible for the R&D pipeline and a member of the R&D Board of Directors. In addition he served on several of the commercial Operating Company Boards and key pharmaceutical group decision-making committees. Dr Willsbegan his career at Hoffmann-La Roche where he spent 10 years in several roles of scientific responsibility. Much of Dr Wills' accomplishments are related to his R&D career, which included the successful development of over 30 NDA's, PLA's, MAA's in multiple therapeutic areas. He has authored over 40 peer reviewed research articles, 5 book chapters, and 50 professional presentations or abstracts in the area of pharmacokinetics. Dr Wills holds a B.S. in Biochemistry and an M.S. in Pharmaceutics from the University of Wisconsin and a Ph.D.
in Pharmaceutics from the University of Texas.